Hepatocellular carcinoma (HCC) remains difficult to treat due to a lack of effective treatment options. While various drugs have shown promising preclinical results, poor drug combination design results in less successful treatment of HCC. This collaborative work with Dr Cheng Ean Chee, A/Prof Glenn Bonney and team, lead by A/Prof Edward Chow, has found that drug combination design can be improved through the use of their drug combination prediction platform to identify combination therapies that are of high therapeutic potential for HCC.

Read more: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377092/